1-3 of 3
Philip Thompson
Close
Sort by
Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Alexandre Bazinet, Tapan Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, Yesid Alvarado, Fadi G. Haddad, Sherry Pierce, Graciela Nogueras Gonzalez, Abhishek Maiti, Koji Sasaki, Musa Yilmaz, Philip Thompson, William Wierda, Guillermo Garcia-Manero, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3284–3296.
https://doi.org/10.1182/bloodadvances.2022009391
Published: 2023
Includes: Supplemental data
Journal Articles

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Clinical Trials & Observations
Nitin Jain, Jayastu Senapati, Beenu Thakral, Alessandra Ferrajoli, Philip Thompson, Jan Burger, Sreyashi Basu, Tapan Kadia, Naval Daver, Gautam Borthakur, Marina Konopleva, Naveen Pemmaraju, Erin Parry, Catherine J. Wu, Joseph Khoury, Carlos Bueso-Ramos, Naveen Garg, Xuemei Wang, Wanda Lopez, Ana Ayala, Susan O’Brien, Hagop Kantarjian, Michael Keating, James Allison, Padmanee Sharma, William Wierda
Journal: Blood Advances
Blood Adv (2023) 7 (10): 1958–1966.
https://doi.org/10.1182/bloodadvances.2022008790
Published: 2023
Includes: Supplemental data
Journal Articles

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

Clinical Trials & Observations
Bachar Samra, Joseph D. Khoury, Kiyomi Morita, Farhad Ravandi, Guillaume Richard-Carpentier, Nicholas J. Short, Siba El Hussein, Philip Thompson, Nitin Jain, Hagop Kantarjian, Elias Jabbour
Journal: Blood Advances
Blood Adv (2021) 5 (20): 3913–3918.
https://doi.org/10.1182/bloodadvances.2021004427
Published: 2021
Includes: Supplemental data